FDA, Abbott, and 15 Other Major Brands: Infant Formula Safety Confirmed in Tests, Stricter Regulations Anticipated
Largest Infant Formula Safety Verification in History
The U.S. Food and Drug Administration (FDA) recently conducted chemical contaminant tests on 312 infant formula products from 16 brands distributed in the U.S. market and released the results. This investigation represents the most extensive infant formula safety assessment to date, generating over 120,000 data points related to heavy metals, pesticides, and per- and polyfluoroalkyl substances (PFAS). This national initiative aimed to restore regulatory confidence following the large-scale infant formula shortage crisis that began with Abbott Laboratories' voluntary recall in 2022. The results demonstrated that the majority of products contained no detectable levels of contaminants or only trace amounts below safety limits, confirming that the U.S. infant formula supply chain is generally safe.
Closer to Zero Initiative and Contaminant Control
This assessment was conducted as part of the FDA's 'Closer to Zero' initiative, a long-term project aimed at minimizing infants' exposure to harmful substances. The tests meticulously measured levels of heavy metals such as lead, cadmium, arsenic, and mercury, as well as 318 different pesticide ingredients, including glyphosate. Fortunately, all samples showed heavy metal levels significantly lower than the U.S. Environmental Protection Agency (EPA)'s drinking water standards, alleviating market concerns. However, due to concerns about the potential negative impact of even trace amounts on infants' neurological development with long-term exposure, the FDA will continue to require manufacturers to improve their processes.
Operation Stork Speed: Modernizing the Supply Chain
The FDA is comprehensively modernizing the infant formula industry's chronic supply chain bottlenecks and regulatory delays through 'Operation Stork Speed,' officially launched in March 2025. This initiative also involves revising the nutrient requirements, which have not been updated since 1998, to align with the latest scientific standards. This presents companies with the burden of renovating production facilities and diversifying raw material sources, while simultaneously creating a regulatory framework that facilitates the rapid introduction of safe new products to the market. Major companies are now facing the challenge of significantly increasing their investment in research and development (R&D) and quality assurance/quality control (QA/QC) to meet the new standards.
Changes in the Competitive Landscape of an Oligopolistic Market
The U.S. infant formula market is currently estimated at approximately $4.5 billion to $6.6 billion annually, with four major companies – Abbott (Similac brand), Reckitt (Enfamil brand), Nestlé (Gerber brand), and Perrigo (private label) – controlling 99% of the market, creating an extreme oligopoly. Following the FDA's large-scale verification, these major companies are expected to further solidify their market dominance and actively utilize safety indicators in their marketing efforts. However, with stricter safety regulations and increased testing, the barriers to entry for new companies will become even higher.
Continuous Market Monitoring and Institutionalization
The FDA has made it clear that this announcement is not a one-time event but will be expanded into a continuous regulatory monitoring program. Follow-up compliance sampling will continue to be conducted on newly introduced brands and additional product lines. The regulatory authorities' strong commitment to ensuring consumer confidence is expected to ultimately stimulate the growth of the premium organic and functional infant formula market. Companies that fail to meet the nutritional and manufacturing standards will be phased out, and the market will be reorganized around leading companies that demonstrate global-level supply chain transparency.
The U.S. infant formula market, valued at approximately $4.5 billion to $6.6 billion annually, is dominated by Abbott Laboratories (ABT), Reckitt (RKT), Nestlé (NSRGY), and Perrigo (PRGO), which collectively control over 99% of the market. The FDA's recent chemical contaminant testing of 312 samples, generating 120,000 data points, serves as a short-term positive factor by dispelling existing safety concerns. However, the regulatory enhancements embodied by the Closer to Zero initiative and Operation Stork Speed may lead to additional cost increases in the medium to long term. While infant formulas do not undergo the typical Phase 1/2/3 clinical trials required for general pharmaceuticals, they are subject to premarket notification and growth monitoring studies, making compliance with quality regulations a critical competitive advantage. From an investor and industry perspective, the market dominance of leading oligopolistic companies capable of absorbing increased quality assurance (QA) costs is likely to be further strengthened. With stricter inspection standards preventing competitors from free-riding, the market is expected to be reorganized around leading companies, leading to increased margins for premium, safety-certified products.